Benzinga | Nov 9, 2021 11:06AM EST

Cara Therapeutics Q3 EPS $(0.02) Beats $(0.40) Estimate, Sales $20.27M Beat $11.21M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.40) by 95 percent. This is a 94.29 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $20.27 million which beat the analyst consensus estimate of $11.21 million by 80.84 percent. This is a 118.78 percent increase over sales of $9.27 million the same period last year.